Liminal BioSciences
- Gary Bridger
Gary Bridger
Interim Chief Scientific Officer at Liminal BioSciences
Dr. Bridger has extensive experience in leading research and development through to commercialization. Dr. Bridger previously served as Executive Vice President of Research and Development at Xenon Pharmaceuticals Inc., Senior Vice President of Research and Development of Genzyme Corporation and co-founded AnorMED Inc., eventually acquired by Genzyme.
Timeline
Interim Chief Scientific Officer
Current role
Board Member & Strategic Scientific Adviser
Related people
Jonathan Wall
Co-Founder & Interim Chief Scientific Officer at Attralus Therapeutics
Jeno Gyuris
Interim Chief Scientific Officer at Tvardi Therapeutics
Claudia Mitchell
Interim Chief Scientific Officer at Coave Therapeutics
Kevin McAllister
Interim Chief Scientific Officer at SOM Biotech
Sharon Rosenzweig-Lipson
Interim Chief Scientific Officer at Life Biosciences